XFOR · X4 Pharmaceuticals Inc
United States · RS rating 35 · As of 2026-11-03
| Price | 3.17 USD |
|---|---|
| 1-day change | -5.4% |
| RS rating (overall / 1M / 3M / 12M) | 35 / 81 / 27 / 36 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 7 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +18.8% |
| Sales growth Q/Q | +45.5% |
| Distance from 52-week high | +32.1% |
| Market cap (USD) | $389.1M |